MariMed (MRMD) Expected to Announce Quarterly Earnings on Wednesday

MariMed (OTCMKTS:MRMD) is expected to be issuing its Q4 2025 results after the market closes on Wednesday, March 4th. Analysts expect MariMed to post earnings of ($0.01) per share and revenue of $40.80 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 12, 2026 at 8:00 AM ET.

MariMed Stock Performance

OTCMKTS:MRMD opened at $0.09 on Wednesday. The stock has a market capitalization of $33.63 million, a P/E ratio of -2.13 and a beta of 1.13. The company has a current ratio of 1.06, a quick ratio of 0.35 and a debt-to-equity ratio of 1.34. MariMed has a 1 year low of $0.07 and a 1 year high of $0.23. The firm has a 50 day moving average of $0.09 and a 200-day moving average of $0.11.

Analyst Ratings Changes

Several analysts have recently commented on the company. Ventum Financial cut MariMed from a “strong-buy” rating to a “hold” rating in a report on Friday, November 7th. Zacks Research raised shares of MariMed from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. One investment analyst has rated the stock with a Strong Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

About MariMed

MariMed Inc is a multi‐state cannabis company focused on the development, ownership and operation of regulated facilities for the medical and adult‐use cannabis markets. Headquartered in New Bedford, Massachusetts, the company cultivates, processes and dispenses cannabis through an integrated business model that encompasses cultivation, formulation, manufacturing and retail operations. MariMed operates under its own licensed brands and through strategic partnerships to expand its presence across the United States.

The company’s product portfolio includes branded flower, pre‐rolls, vaporizer cartridges, tinctures, edibles and topicals designed to meet a range of consumer and patient needs.